- Home
- LNKB vs SERA Comparison
LNKB vs SERA Comparison
Compare LNKB & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- SERA
- Stock Information
- Founded
- LNKB 2018
- SERA 2008
- Country
- LNKB United States
- SERA United States
- Employees
- LNKB N/A
- SERA N/A
- Industry
- LNKB
- SERA Precision Instruments
- Sector
- LNKB
- SERA Health Care
- Exchange
- LNKB Nasdaq
- SERA Nasdaq
- Market Cap
- LNKB 270.4M
- SERA 90.6M
- IPO Year
- LNKB N/A
- SERA 2021
- Fundamental
- Price
- LNKB $7.40
- SERA $3.19
- Analyst Decision
- LNKB Strong Buy
- SERA
- Analyst Count
- LNKB 1
- SERA 0
- Target Price
- LNKB $9.00
- SERA N/A
- AVG Volume (30 Days)
- LNKB 34.1K
- SERA 111.1K
- Earning Date
- LNKB 10-27-2025
- SERA 11-05-2025
- Dividend Yield
- LNKB 4.12%
- SERA N/A
- EPS Growth
- LNKB N/A
- SERA N/A
- EPS
- LNKB 1.01
- SERA N/A
- Revenue
- LNKB $121,982,000.00
- SERA $108,000.00
- Revenue This Year
- LNKB $18.26
- SERA $257.66
- Revenue Next Year
- LNKB N/A
- SERA $435.22
- P/E Ratio
- LNKB $7.22
- SERA N/A
- Revenue Growth
- LNKB 79.01
- SERA 0.94
- 52 Week Low
- LNKB $6.09
- SERA $1.37
- 52 Week High
- LNKB $7.98
- SERA $9.13
- Technical
- Relative Strength Index (RSI)
- LNKB 52.53
- SERA 59.25
- Support Level
- LNKB $7.03
- SERA $3.01
- Resistance Level
- LNKB $7.53
- SERA $3.50
- Average True Range (ATR)
- LNKB 0.19
- SERA 0.27
- MACD
- LNKB -0.00
- SERA -0.01
- Stochastic Oscillator
- LNKB 47.00
- SERA 42.75
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.